Welcome to Specialty Care
Oral and Maxillofacial Surgery
Oral and maxillofacial surgery is performed to treat diseases and defects involving both the functional and aesthetic aspects of the hard and soft tissues of the oral and maxillofacial region. Dr. provides a history of over 20 years experience as he offers the following services:
Our business office staff is experienced with insurance procedures and can answer most questions regarding billing or insurance coverage.
Have you signed up for MR Thoughtline? It’s Guy Repeller’s new text-based service that lights up phone screens with great bits from around the internet, chances to chat with cool people, and digital recesses to help your mind take a break from the news in favor of a dish, physical activity or, trust us, very helpful WFH clothing ideas. Subscribe here.
I am not one of those individuals who discovers the flaws of their better half “lovely,” so while Austin is a fantastic individual, I will never ever forgive him for his ability to go to sleep within minutes of getting in bed. As somebody who has actually frequently battled sleeping disorders, and who practically constantly needs to court sleep like an unrequited love interest, viewing this take place night after night feels like the supreme betrayal– by him (for abandoning me, naturally), but likewise by my own body for struggling to do something that ought to possibly come naturally.
I have to preserve a strenuous sleep health protocol if I do not want to remain awake into the wee hours, chewing on immediate ideas: what I should have for supper the next day, whether somebody seethes at me, the number of followup emails is too many followup emails, and oh, did I remember to buy more dental floss? My protocol for falling asleep as expediently as possible includes taking a bath, cutting out screen time an hour before bed, and reading for a minimum of 30 minutes. Often life gets in the method and I can’t do all of that, or often I do all of that and I still feel large awake– for this reason why I keep a supply of CBD supplements in my nightstand drawer.
I first tried CBD a little over two years ago when the acronym (brief for “cannabidoil”) was just beginning to get in mainstream vocabulary. I discovered it handy for fighting my sleep problems right off the bat, but I ultimately discovered it even more valuable after continuing to experiment with which specific items work best for me. I’ve tested dozens of CBD products ever since, with a wide variety of results. The more I’ve tried, the pickier I have actually become, which is why I aspire to share the two that have proven to be most efficient in my experience: Gossamer Sunset, and Not Pot Vegan CBD Gummies
See All 2
I go with one or the other depending on the circumstance at hand. Gossamer Sunset is what I utilize most frequently– whenever I pick up that I’m going to have problem going to sleep, I’ll position a dropper’s worth under my tongue for 30 seconds before brushing my teeth (the oil doesn’t taste remarkable, so it’s nice to follow it with something minty fresh). The effects are mild sufficient to practically be imperceptible, but I definitely discover myself going to sleep more quickly after taking it, and I awaken sensation absolutely revitalized with zero grogginess. If you have an interest in finding out more about the active components in this specific CBD mix, or about what CBD remains in basic, Gossamer’s site has an excellent guide
Not Pot Vegan CBD Gummies are more similar to the idiom, “highlight the huge guns”– simply put, they’re what I rely on when I need a more powerful sleep induction. In addition to 10 mg of CBD, each gummy is also infused with 100 mg of L-theanine, an amino acid originated from green tea that research studies have revealed can help alleviate anxiety, and this mix seems to be exceptionally effective when it comes to calming my mind and getting me into sleepy-time mode. I take them sparingly due to the fact that I do discover that I am a bit drowsier than typical when I get up in the early morning after having one, but it’s barely noticeable compared to what I have actually experienced with Ambien or NyQuil P.M.
Though neither Gossamer nor Not Pot manufacture items with THC– the psychedelic compound in cannabis that makes you feel “high”– they share a dedication to acknowledging the complicated sociopolitical dynamics of weed and promoting criminal justice reform together with legalization. Not Pot uses a portion of their revenues to spend for somebody’s bail on a monthly basis, and Gossamer has devoted complimentary advertisement area in their publication for non-profits that do work associated to criminal justice reform and drug policy concerns, in addition to making donations to companies like the Women’s Jail Association. (For a helpful analysis of these problems as they connect to the mainstreaming of marijuana, I extremely recommend this piece by Otegha Uwagba).
After lots of, many years of battling sleep issues– not to discuss irrational jealousy of people who do not, I’m so grateful these CBD items exist. I’ve been particularly appreciative of them over the last couple of months, as the effect of quarantine on my psychological health has made things even more difficult sleep-wise. If you remain in the exact same boat, I’m curious what has been useful for you. Have you tried taking CBD? If so, from what brands? Does it fill you with petty rage when you witness another person falling asleep as soon as their head hits the pillow? Please inform me I’m not alone.
Man Repeller editors endorse items we genuinely like. If you wind up purchasing something through our links, we may earn an affiliate commission. Find out more here
Harling is the Brand Name Director at Male Repeller.
Whether you’re still practicing strict stay-at-home safety measures or carefully exploring the parts of the nation that are meticulously reopening, it’s never ever been more important to sanitize your hands. While it’s apparent to many that clean hands are crucial during times of pandemic, Dr. Joshua Zeichner, M.D., Director of Cosmetic and Medical Research Study at New york city’s Mount Sinai Medical facility, alerts that passionate hand care is always crucial, particularly when taking a trip:
” Whether there is a pandemic or not, tourists should constantly be extra alert about hand washing.
Sadly, as lots of are currently experiencing, increased cleaning can cause a host of skin concerns, particularly when the wrong products and strategies are used. As Dr. Zeichner describes, “Lots of people end up interrupting the skin barrier. When there are cracks in the outer skin layer, the skin loses hydration and ends up being inflamed.”
Happy Hands is a four-part series rounding up the best products to keep your hands clean and comfortable during the COVID-19 pandemic now, and as you take a trip back into the world after. In this edition, the 10 finest cold cream and moisturizers from A lot of Extreme to Finest for Nature Nuts are presented.
Finest for Beginners
Bringing CBD to the masses with accessible rate points and easy in-store access (look for it at CVS locations this summer season), KARIBO CBD Infused Hand & Body Cream is an every-day product ideal for the CBD-curious. With a low concentration of hemp-derived CBD (about 8.3 mg per ounce) and an expense simply under $20 for a tremendous 12 ounces, the soothing lotion is a no-risk venture into the relaxing and restorative advantages of CBD integrated with the moisturizing homes of aloe vera and vitamins A and E.
Many Budget-friendly Power
If your hands are experiencing overuse and over-washing (or you’re determined to prevent this) and you’re ready for a more major concentration of CBD, Nourishing Body Cream from Anzie Blue provides more than 60 mg per ounce in a fast-absorbing cream at $60 for a four-ounce bottle. In addition to the therapeutic advantages of CBD leaves instilled in the cream, active ingredients like shea butter, coconut oil, mango seed butter and aloe leaf juice moisturize while chamomile and ylang further relax your skin and senses.
Best for Pure Power
The neediest hands are going to desire the greatest relief and ought to turn to 500 MG CBD Hand Cream from Likewise Organics, offering 250 mg per ounce of whole-plant CBD infusion in mix with vitamin C and lavender oil to soothe and recover dry and delicate skin.
Best for Routine Use
For an unnoticeable barrier that maintains your skin’s natural moisture and protects your hands from irritants, apply Avon Care Silicone Glove routinely, and particularly prior to exposing your hands to any ecological stress factors. The skin-softening formula decreases dryness and helps to recover currently dry and split hands while all at once working to prevent more damage with a light cream.
Finest for Strong Use
If your hands will be exposed to serious skin tension (including relentless cleaning) either from work or experience, buy Gloves In A Bottle for effective security. The waterproof cream forms a liquid glove that lasts 4-12 hours and will not clean off, trapping natural moisture, offering additional hydration and shielding your skin from environmental irritants, consisting of the required soaps sanitizers that often dry hands.
Food Lover Fragrance
Most Citrusy Sugary Food
Orange-forward with a hint of pink grapefruit and a sticking around whisper of lemon and lime, Energizing Citrus Body Cream from A Lady’s Got ta Spa!
Finest for Beach Bums
It’s difficult not to associate the aroma of coconut with the beach, and Coconut Milk & Sandalwood Deep Wetness Hand Cream from Soapbox will psychologically carry you to the most unique shores.
Finest for Nature Nuts
Whether your prefer the garden or the woods, if you like to get your hands dirty with earth you’ll be nuts for the variety of Spit Polish Hand Lotion scents readily available from Duluth Trading Co. With hydrating oils of sunflower, coconut, jojoba and hempseed, the light-weight creams range in naturally stimulating scents from Tominto(tomato and mint) and Pure Lavender to Cedar & Fir and Lost in the Woods Obviously, if your nose requires a break, you can bring the Odorless lotion as a backup.
The Majority Of Severe
When the damage is done and your hands remain in extreme requirement of healing and rehydration, reach for Theraderm’s Extreme Dry Skin Treatment Longer lasting than typical moisturizers, Extreme Dry Skin Therapy consists of 20%highest-grade lanolin to form a protective oil barrier on your skin’s surface area, allowing the natural lipid barrier to fix and replenish, while likewise permeating to the deepest layers of your skin to supply moisturizing relief.
For antioxidant protection and abundant, multi-layer moisturization from lactic acid and vitamins A, C and E, apply LCA fx141 Hand and Body Replenisher from Priori. Beyond long-lasting hydration, the sericin in this emulsion visibly corrects your hands by smoothing wrinkles, stretch marks and rough patches with daily application (one or two times each day will do it for many), for a bonus beauty boost with your comforting relief.
You can discover Pleased Hands, Part 1: Soaps and Sanitizers here
You can discover Pleased Hands, Part 2: Lotions here
( These particular items are not backed by Dr. Zeichner, whose participation in this series is entirely as a specialist on the general importance of skin care. Consult your physician or skin doctor to discuss the very best practices and products for you.)
Many of the best stocks to buy come with a high price tag. This fact is hardly surprising: Companies with exciting growth prospects will generally attract a lot of attention, and as investors load up on shares of these companies, their stock prices rise accordingly. However, it is still possible to find good stocks to buy on a budget, especially considering that the ongoing COVID-19 pandemic has led to so many great stocks being thrown in the discount bin. With that in mind, here are two excellent cannabis stocks that are currently going for less than $10 apiece: Charlotte’s Web Holdings (OTC:CWBHF) and Planet 13 Holdings (OTC:PLNH.F).
Charlotte’s Web Holdings
Charlotte’s Web provides cannabidiol (CBD)-derived products such as gummies and oils, and the company stands as one of the leading players in this industry. Charlotte’s Web continues to expand its footprint in this market, too. The company’s products can now be found in more than 10,000 stores across the U.S., and that number is set to increase soon: Charlotte’s Web recently announced it would acquire Abacus Health, which provides over-the-counter CBD products in more than 12,000 stores, in an all-stock transaction valued at $69 million.
Image source: Getty Images.
This transaction, which is expected to close sometime this year, will significantly increase Charlotte’s Web’s footprint in its market and diversify the company’s product offering. Still, detractors may point to a significant obstacle that could hinder Charlotte’s Web’s growth: Last year, the U.S. Food and Drug Administration (FDA) famously informed consumers about the dangers of CBD, warning that the substance can cause liver damage.
The FDA has also issued warning letters to several companies making unproven claims about the health benefits of their CBD-based products. These developments did affect Charlotte’s Web’s financial performance; CEO Deanie Elsner noted that “in November, the FDA issued several warning letters to certain CBD companies which caused our customers to pull back across all channels, negatively impacting the sector and our sales.”
There is at least one other way in which the FDA is proving to be a thorn in Charlotte’s Web’s side. The company argues that its growth is being hindered by the lack of regulatory direction regarding CBD products. But even with these obstacles, I believe investors would do well to bet on Charlotte’s Web. Not only will the recent acquisition of Abacus Health boost its revenue and profits, but in the long run, the company is ready to profit once the FDA finally does release these regulatory directions.
To quote Elsner again: “The opportunity for Charlotte’s Web will be both the expansion of our distribution breadth across national retailers, in addition to the expansion of our portfolio depth within each retailer. The catalyst for this significant revenue inflection point would be the FDA setting guidelines for dietary supplements.”
In my view, these factors make Charlotte’s Web’s stock a buy, especially considering that its shares are trading for just under $7 apiece at the moment.
Planet 13 Holdings
Planet 13 Holdings is a marijuana dispensary operator headquartered in Las Vegas. But this isn’t just any weed store: Planet 13 has managed to differentiate itself from its operators and carve out a niche for itself with its flagship location in Las Vegas, which it calls a “cannabis entertainment complex.” Simply put, the focus of this particular dispensary is on the experience of the customers as much as on the cannabis products the company sells.
Planet 13′ “Superstore” boasts a restaurant and a coffee shop, among other things. And the store benefits from one significant advantage — location. Planet 13’s superstore is located near the Las Vegas Strip, which means it is almost guaranteed to attract a significant number of visitors year-round — unless, of course, there is a pandemic forcing people to practice social distancing. Thanks to its unique business model, Planet 13 Holdings performed well last year.
The company had more than a million visitors during the year, accounting for about 9% of cannabis sales in a competitive market in Nevada. Last year, while many cannabis companies were busy shedding much of their value, Planet 13 Holdings’ stock soared by almost 80%. Sure, the company isn’t doing nearly as well this year, but that’s hardly surprising given the current market conditions. Looking forward, though, Planet 13 Holdings could be a big winner in the long run.
The company has plans to expand its presence and open eight more cannabis superstores in several high-profile U.S. cities over the next five years. Planet 13 Holdings is still in the early stages of its growth, and as the company expands its presence, its revenue and earnings could follow suit. That’s why investors would do well to buy shares of the cannabis company at a measly $1.25 apiece.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Planet 13 Holdings Inc. The Motley Fool recommends Charlotte’s Web. The Motley Fool has a disclosure policy.”>
On May 20, Charlotte’s Web, the Colorado-based CBD giant and arguably one of the biggest names in legal cannabis, announced that the company was awarded its second federal patent on a cannabis plant.
Unlike the company’s 2018 plant patent on a Farm Bill-compliant high-CBD hemp cultivar—which was the first hemp strain to receive federal intellectual property protection—US Patent No. 10,653,085 is a utility patent.
This means, after satisfying a more rigorous process, including dropping off thousands of seeds at an official United States depository, Charlotte’s Web now claims as its intellectual property both the cultivar of hemp the company calls CW1AS1 as well as “methods” of plant production and cannabinoid extraction.
Okay! But so what? Why patent a hemp strain—why patent two? What does it all mean? Does Charlotte’s Web now have legal claim to the entire CBD game?To the last question, no. And as for what this means, for normal people and cannabis consumers, very little. For patent attorneys or competitors of Charlotte’s Web in the CBD industry, it portends a little more, but just a little.
At least for now, cannabis patents like this one aren’t really intended to defend intellectual property in court—which is where a patent has its most practical value.
No, this patent is probably meant for the market. Patents like this exist mostly for companies to satisfy and woo investors, for whom a company’s ability to say “Look! I have a patent” might be the difference between signing a check, or not. And like all publicly traded cannabis companies, Charlotte’s Web has a lot of spooked and angry investors who need pleasing.
Patents “generate interest in the company, and are something investors would look at,” said Jonathan Hyman, a patent attorney and partner at the Los Angeles office of Knobbe Martens.
Whether Charlotte’s Web would enforce the patent, and how, “remains to be seen,” he added.
Company officials were not available to discuss the matter. In a statement provided by Sylvia Tawse, the company’s director of communications, CEO Deanie Elsner said Charlotte’ Web “will continue to pursue patent protection for unique and novel hemp genetics developed by our horticulture division.” Whether that meant there are any pretenders the company plans to sue, she did not say.
Though cannabis-related patent applications have been a thing since well before legalization and have tripled since 2015, as IP Watchdog noted, the mere phrase “cannabis patent” can still be triggering in cannabis circles. Patent talk can often lead to galaxy-brain thinking like the “Monsanto is supporting legalization in order to steal cannabis” or the “Philip Morris is buying up land in Humboldt County” conspiracy theories.
In the case of Charlotte’s Web, the company’s already locked up what’s probably its most valuable asset: its name. Charlotte’s Web is named for Charlotte Figi, the sufferer of childhood epilepsy who enjoyed relief from her symptoms after taking an extract of high-CBD cannabis grown by the Stanley brothers (and who died earlier this month after contracting COVID-19).
The world came to know Charlotte Figi and the Stanley brothers, seven photogenic Coloradans whose first names all begin with J, after they were prominently featured in a 2014 CNN special hosted by Sanjay Gupta. A very famous children’s book and a very famous and recognizable name, the company was sure lock down the name “Charlotte’s Web” with a trademark—one the company is currently defending in federal court, after a rival company dared market CBD products called Charlotte’s Web.
That’s what patents are for in terms of the law. But markets are another matter—and it’s worth observing that the company went public after securing its first patent.
Like almost all publicly traded companies in the cannabis sector, Charlotte’s Web is stuck in high-loss doldrums after hitting early peaks.
For the past week, shares in Charlotte’s Web have been trading in the $7 to $9 range in the Toronto Stock Exchange. That’s a big gain from the $4.24 seen at the company’s mid-March nadir, but still far below last summer’s high-water mark of $28.21, set in August.
Despite being sold in more than 11,000 stores, the company still lost $1.7 million in 2020—a hit smaller than other companies in the cannabis sector, but still in the red.
Patenting hemp genetics and the processes to achieve them won’t be enough to rescue the rest of the company’s lost value. But if Charlotte’s Web wants to be a global CBD brand, with product in supermarkets and convenience stores all over the globe—and why wouldn’t it?—this means something.
“Having this patent, that they can wave around and say, ‘Hey, we’ve got coverage on it, and it’s the best variety [of CBD rich hemp] that you’re going to get,’ ” said Andrew Merickel, who holds a Phd in neuroscience and is also an attorney and partner at the San Francisco office of Knobbe Martens. “That’s pretty valuable.”
How valuable? That’s all up to the logic of the market.
‘There Is An Active Discussion Of CBD Happening Across The Country,’ Says A New Report. And That Spells Opportunity.
In 2017, when celebrity host (The View) Whoopi Goldberg was enjoying the high point of her then-new CBD brand, Maya & Whoopi, a reporter asked what the next step was. “World domination,” Goldberg joked at the time.
She might have been onto something.
Goldberg this year parted ways with her business partner, Maya Elisabeth; the result was that their company folded. But if Goldberg back in 2017 was predicting a big future for CBD startups, she wasn’t off the mark, judging from a the findings of a new survey from New Frontier Data.
“The newness of the CBD experience for most consumers suggests there remains significant opportunity for well-developed brands to attract consumer attention and capture market share from existing market leaders,” the report says. A big reason why startups might have an edge, the researchers imply? The novelty factor.
“Consumers have not been using the products with sufficient longevity to create durable brand loyalty that is difficult to dislodge,” the report says.
To compile the study, New Frontier Data surveyed 4,074 U.S. adults in mid-March. The survey population consisted of 26% of subjects who earned less than $30,000; 27% earning $39,000 to $59,999; 27% earning $60,000 to $89,999; and 16% earning $90,000 and up.
Among the report’s chief takeaways:
Familiarity with CBD is an important factor
· CBD is hardly unknown to the American mainstream. “Nearly 9 in 10 Americans are familiar with CBD,” the report says. Some 86% of those surveyed had heard of CBD, and a majority (55%) were interested in learning more. Younger cohorts tended to be more interested than older groups.
· Word of mouth is a common thread: Nearly 3 in 4 (73%) of those surveyed who’d heard of CBD reported having had a conversation about it, including the 67% who had not consumed it. People reported that their conversations were largely positive.
· Positive associations: 51% of those surveyed knew a friend or family member who’d used CBD, and nearly 1 in 5 (17%) had recommended CBD to someone else.
· Frequency: Among Americans who reported ever having consumed CBD, 40% said they did so at least once a week, with older consumers using it more frequently than younger ones.
· CBD consumers seem to be evangelists. A majority, 56%, said they had recommended CBD products to someone else.
Stress and pain are major reasons for use
· Three in five (60%) of consumers surveyed reported using CBD in a context that might be called “unwinding,” such as relaxation, relief of stress or anxiety reduction. The primary use, however (41%), was pain management.
Means of Consumption
· Oils and tinctures led the way, at 38% (of the ways in which consumers surveyed consume CBDs). Topicals were the next most widely used method, at 19%; then: food or drinks, 18%; flower, 8%; pills/capsules, 7%; and vaping, 7%.
· Some 43% of consumers said they used less than 30 mg. a day; 22% reported using 50 mg. or more; and 12% used 100 mg. or more a day.
· Some 65% of consumers surveyed said CBD had positively affected their quality of life. Only 2% described a negative effect.
Level of expenditure
· Most consumers (59%) said they spent less than $50 a month on CBD.
· Some 46% of male consumers surveyed said they used CBD at least once a week, versus 36% of women in the survey population.
· On average, men spent more for CBD than did women. Men were more likely (21%) than women (12%) to spend more than $100 per month. Purchasers ages 35 to 54 were the most likely (21%) of any group to spend more than $100 per month.
· CBD purchasers reported being generally happy with the products they were able to purchase, depending on the regulations in their geographic area; 71% agreed they were satisfied with their purchases.
· When selecting which CBD product to purchase, price and quantity of CBD were the most important factors to those surveyed. Convenience of location and service from staff were also important criteria.
· Some 51% of purchasers said they usually purchased familiar brands. About 29% said they would be likely to purchase CBD in the next six months.
Where the Opportunities Lie
For CBD startups, the women’s market for might be one smart place to focus, considering that male survey respondents were far more likely (21%) than women (12%) to spend more than $100 per month.
Another wise move might be to market only products backed by clinical studies and clear, authoritative information. The reasons here would be the importance consumers put on reliable information, as well as the strict FDA restrictions against promoting CBD for medical purposes.
Infusions as a method for consumption also seem to be of growing interest, while smoking is losing users due to social norms, especially during the current COVID-19 crisis when so many cannabis medical users are housebound.
Finally, given the anxiety during the crisis and the prevalence of word of mouth in spreading information about CBDs, companies might want to turn to such marketing channels as referral discounts, loyalty programs and high-production-value consumer testimonials, according to the New Frontier Data report.
In recent weeks, Aurora Cannabis ( NYSE: ACB) stock has seen brand-new life. All of it began with the company releasing its third-quarter 2020 results on May 14, which revealed 18%profits growth from the previous period. A dedication to more improving its costs likewise offered investors a reason to be hopeful that success might not be just a pipeline dream.
Then, on May 20, the marijuana manufacturer also announced it was getting Reliva, a cannabidiol (CBD) brand name that would enable it to permeate the U.S. market. As interesting an opportunity as that may appear initially glimpse, here’s why investors shouldn’t put too much stock in it.
It’s going into an already crowded hemp market
Lots of headlines promote Aurora’s current acquisition as the company getting into the U.S. CBD market. All kinds of CBD aren’t legal in the U.S. (federally), and Aurora can’t use non-hemp items that consist of more than 0.3%of tetrahydrocannabinol (THC).
Image source: Getty Images.
The bright side is that according to research study companies BDS Analytics and Arcview Marketing Research, the total CBD market in the U.S. is still anticipated to reach $20 billion by 2024, up from simply $1.9 billion in2018 The projection didn’t break out the split in between hemp and non-hemp products. And the problem is that the rosy outlook for CBD does not imply the chance is going to translate into substantial development for Aurora.
That’s due to the fact that Aurora will not just be contending with other U.S. business for market share, but with Canadian pot stocks that are also looking to take benefit of the opportunities in the hemp market.
Julie Lerner, who is CEO of the PanXchange where hemp is traded, validated in January that there was much more supply than need for hemp. She anticipates market prices to come down as an outcome of all the competition. That’s not going to bode well for a company like Aurora, which is attempting to enhance on its margins and get closer to profitability.
Having access to countless places doesn’t ensure growth
In the news release revealing the acquisition of Reliva, there wasn’t a whole lot of details on how big of a gamer the company is in the hemp market. Aurora referred to Reliva as “a leader in the sale of hemp-derived CBD items in the United States,” there wasn’t anything to quantify or justify that other than to state that its items were sold in more than 20,000 U.S. places.
Hemp-derived CBD company Charlotte’s Web ( OTC: CWBHF), offers its products in less locations, and it has far more powerful sales.
A year back, the company tape-recorded sales of $217 million when its products were in more than 6,000 locations. The increase in places over the previous year hasn’t resulted in a surge in sales for Charlotte’s Web, and Aurora investors shouldn’t make the mistake of assuming more areas imply higher revenue.
The move doesn’t make Aurora a much better buy
Aurora anticipates Reliva to assist the Alberta-based pot manufacturer inch closer to achieving a positive adjusted earnings prior to earnings, taxes, devaluation, and amortization (EBITDA) figure. The acquisition might assist play a small part in improving Aurora’s bottom line, but the company still has a lot of work to do in enhancing its financials.
The only certainty, it appears, is that the offer will lead to more dilution for investors. The business prepare for the deal will close in June, and it will cost Aurora as much as $45 million in shares.
The acquisition is a modest one for Aurora that will assist add to its top line, however that has to do with it; Aurora stays a risky buy, and one quarter and one acquisition isn’t going to alter that. The pot stock is still down more than 80%over the past 12 months, especially worse than the Horizons Cannabis Life Sciences ETF ( OTC: HMLSF), which has actually fallen by 60%.
So, things are pretty terrible right now. The world feels like a dumpster fire that spread to the bed of a garbage truck before setting the entire landfill ablaze. If you’re feeling overwhelmed or anxious or generally irritable, that’s perfectly natural, and there are plenty of tried-and-true methods you can use to lift your spirits: talk to a therapist, get in a good stretch, maybe turn on a soothing podcast. But what if there was something simpler, more immediate, and less expensive than that mail-order CBD subscription of yours? What if you could just throw on a pair of sunglasses and suddenly feel better, calmer, happier?
That’s the promised voodoo behind the first collection from Futuremood, a Bay Area eyewear brand that launched earlier this week. All of their sunglasses feature specially tinted lenses—using a new technology called Halochrome, developed by the German lens savants at Zeiss—that purportedly alter your mood by manipulating light and color.
There are four colors (or “auras,” as Futuremood likes to call them) to choose from, each one designed to elicit a specific feeling: green is for relaxation; red provides energy; yellow offers focus; blue refreshes your mind. The effect, Futuremood co-founder Michael Schaecher alleges, “is less subtle than CBD, but more subtle than caffeine.” The brand’s extremely extra website markets its wares, somewhat regrettably, as “wearable drugs.”
When Futuremood’s initial press release landed in my inbox, I rolled my eyes so hard that I altered my own mood. But then I looked around at the granola self-care habits I’ve developed, particularly as the days in isolation wear on: I meditate, I drink expensive vegan superfood shakes, I listen to corny Louise Hay affirmations on YouTube. Were Prozac sunglasses that different? If they could ease my existential angst—even by a fraction, even by placebo—then why not give ’em a shot? So I asked Futuremood to send me a few pairs.
What I received were three pairs with the red, blue, and yellow lenses. (Disappointingly, I didn’t get to test green—the “relax and soothe” aura—which I assume Futuremood expects to sell the most of right now.) Despite the techno-crunchy sales pitch—and the complimentary incense in the boxes—the glasses themselves don’t look gimmicky. They come in two frame styles: a classic, Moscot-esque keyhole shape and a chunkier clout goggles situation—all fashioned using top-notch Japanese acetate and gold-plated German hinges. The glasses also do shield your eyes from the sun: all of the lenses have full UV protection, along with anti-glare, anti-scratch, and water-resistant coatings. (Amusingly, the mood-shifting claims are powerful enough to warrant a note that warns not to wear them while driving—wouldn’t want to be too alert or calm on the road.)
I spent a few days testing all three pairs indoors and out—around 30 to 45 minutes at a time, which is how long Futuremood recommends before giving your eyes a break. To answer your question in as unsatisfying a way as possible, the glasses did…something. Did I feel the specific effects that Futuremood ascribed to each color—energy for red, focus for yellow? Not always, not exactly. But each of them yielded novel and, I guess, pleasing sensations. The blue lenses helped to balance out and color correct my apartment’s distinctly yellow, drab overhead lights I’ve been working under for two months now. The yellow pair made everything look a little bit like a Fincher movie: a mildly heightened sense of reality, with the contrast dialed up to 11.
The biggest trip of all were the red frames, which turned everything a searing crimson. It was legitimately disorienting at first, like waking up on an alien world or, as Schaecher puts it, “an underground Berlin club at three in the morning.” This certainly gave me a jolt at first, but more in a panicky my-edibles-just-kicked-in-hard way than a welcome double-shot-of-espresso one. Once I relaxed into the experience, though, it evened out to something akin to an amusing, low-grade lucid dream. I could see them maybe being fun to wear at, say, a music festival, if those ever actually happen again.
Whether or not the Futuremood glasses actively improved my energy is tough to say, but all three shades I tested absolutely put me at a slight remove from my everyday life—which felt nice for a little while. I did feel a soothing buzz during and after my wear tests. I think?
Dr. Ivan Schwab, the director of cornea services at the UC Davis Medical Center, isn’t arguing with the effects, though he doesn’t think it has anything to do with Halochrome™. “I think this falls more in the realm of psychology than it does in optics,” Dr. Schwab told me when I asked if there’s any scientific basis for the claims Futuremood makes about its lenses. The studies Futuremood cites, he said, are largely proprietary tests conducted by Zeiss. But in his view, it comes to how your brain—a product of nature and nurture—interprets color.
“The question I have is: Do other societies—completely different societies, like Amazonian tribes, for example—do they have the same psychology for colors as we do?” he says. He shrugged when I asked if they were some form of dangerous. As long as they had proper UV protection, there’s no harm. Besides to Dr. Schwab’s sense of style: “Those red ones, well, they might shock Elton John, for heaven’s sake.”
Are Futuremood’s sunglasses really combating the compounding anxieties that 2020 keeps hurtling our way? Probably not. But I do find myself reaching for them throughout the day, as I ramble around my apartment. I’ll take all the mood-altering I can get right now.
Futuremood Aurazone 100 sunglasses
Futuremood Aurabliss 5000 sunglasses
Futuremood Auraflow 100 sunglasses
Futuremood Auraboost 5000 sunglasses
Not long ago, previously acquisition-happy marijuana companies put the brakes on spending. Collectively, they lost money much more frequently than they made it — so snapping up new assets to build scale became a less hot idea than it had been a few years ago.
That was then, and this is now. Last week’s big cannabis company news was a throwback to the good old days of 2018 or so, with Aurora Cannabis (NYSE:ACB) signing on the dotted line for a buyout. Another key pot industry event transpiring last week came when a major dispensary operator reporting its latest set of earnings. Here’s more on both developments.
Image source: Getty Images.
Aurora buys Reliva
Canada-based Aurora is reaching across the border for that acquisition. It announced it has agreed to buy U.S. hemp-derived cannabidiol (CBD) products maker Reliva in a deal for roughly $40 million in Aurora common stock, plus up to $45 million over the next two years in cash, stock, or a combination of the two if Reliva meets specific financial goals.
Aurora said it expects Reliva to be “immediately accretive” in terms of every marijuana company’s preferred operational metric — adjusted EBITDA. This would help Aurora, as it’s required by debt covenants to be adjusted EBITDA-profitable overall in Q1 of next year.
Aurora didn’t say whether Reliva is profitable on the bottom line; I’m assuming it’s not if adjusted EBITDA is mentioned in place of net profit/loss. Its annual revenue is $13 million to $14 million, according to a report in MarketWatch; for scale, Aurora’s top line in 2019 hit almost $248 million Canadian ($177 million).
This buy is somewhat surprising, given that Aurora has been in retreat mode since late last year. It suspended construction and expansion activities at two of its facilities, hung a “for sale” sign on one of its greenhouses, and in the wake of the SARS-CoV-2 coronavirus furloughed around 500 of its employees.
While investors can be guardedly positive about some recent news with Aurora, such as its latest set of quarterly results, I don’t think they should jump for joy here.
Yes, CBD products are trendy among certain consumers just now. But they aren’t the big and fast-growing money spinner that would make an acquisition like this have a significant impact.
The company’s balance sheet isn’t particularly strong, and it tends to issue and spend its own stock a bit too much for comfort, in my view. The Reliva acquisition doesn’t move the needle on my generally bearish stance on Aurora — despite some encouraging numbers in its Q3, it was well in the red for the quarter. Meanwhile, it continues to struggle with many of the same difficulties afflicting its Canadian cannabis peers.
Curaleaf’s mixed Q1
The marijuana producer and retailer didn’t hit the average analyst estimate for revenue, but it wasn’t too far away from it. Plus that line item increased by almost 30% quarter over quarter to almost $96.5 million. Net loss, meanwhile, was narrower than expected and a significant improvement over the preceding quarter’s result.
Curaleaf’s retail focus seems to be serving it well; dispensary openings and acquisitions were the moves that helped lift that top-line figure. And in most states — although not necessarily the company’s home of Massachusetts, at least initially — marijuana stores have been classified as “essential” businesses allowed to operate through the coronavirus pandemic. This should help keep the company afloat in the coming months.
It’s sounding a bullish note about the rest of 2020, predicting that both revenue and the bottom line will continue to improve. Meanwhile, the company appears to have enough cash for now, so perhaps it won’t be tapping the debt or equity markets for new funding soon, as it has in the recent past.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”>
A group led by scientists at Baylor College of Medication in partnership with Medterra CBD carried out the first clinical studies to assess the potential restorative impacts of cannabidiol (CBD) for arthritic discomfort in dogs, and the results could lead the way to studying its impact in human beings. Researchers focused initially on these animals because their condition closely imitates the attributes of human arthritis, the leading reason for pain and disability in the U.S. for which there is no reliable treatment.
Released in the journal Discomfort, the research study first showed both in laboratory tests and mouse models that CBD, a non-addictive product derived from hemp (marijuana), can substantially lower the production of inflammatory particles and immune cells associated with arthritis Consequently, the research study revealed that in pet dogs diagnosed with the condition, CBD treatment substantially improved quality of life as recorded by both owner and veterinarian evaluations.
” CBD is quickly increasing in popularity due to its anecdotal health advantages for a range of conditions, from decreasing stress and anxiety to aiding with movement disorders,” said matching author Dr. Matthew Halpert, research study faculty in the Department of Pathology and Immunology at Baylor. “In 2019, Medterra CBD approached Baylor to carry out independent scientific research studies to figure out the biological abilities of numerous of its items.”
In the current research study, Halpert and his colleagues first determined the result of CBD on immune reactions associated with arthritis, both in human and murine cells grown in the laboratory and in mouse models. Utilizing Medterra casts, they discovered that CBD treatment led to reduced production of both inflammatory particles and immune cells linked to arthritis.
The scientists also identified that the result was quicker and more reliable when CBD was provided encapsulated in liposomes than when it was administered ‘naked.’ Liposomes are synthetically formed small spherical sacs that are utilized to provide drugs and other substances into tissues at greater rates of absorption.
Halpert and colleagues next evaluated the result of naked and liposome-encapsulated CBD on the lifestyle of dogs diagnosed with arthritis.
” We studied canines since experimental evidence reveals that spontaneous designs of arthritis, particularly in domesticated canine designs, are more appropriate for examining human arthritis discomfort treatments than other animal designs. The biological characteristics of arthritis in canines carefully resemble those of the human condition,” Halpert stated.
Arthritis is a typical condition in canines. According to the American Kennel Club, it affects one out of five pet dogs in the United States.
The 20 client-owned canines enrolled in the research study were seen at Sunset Animal Medical Facility in Houston. The pet dog owners were arbitrarily provided with identical unidentified medication bottles that consisted of CBD, liposomal CBD, or a placebo.
After 4 weeks of day-to-day treatment, owners and vets reported on the condition of the pet dogs, whether they observed modifications in the animals’ level of pain, such as modifications connected to running or gait. The pet dogs’ cell blood count and blood indicators of liver and kidney function also were examined prior to and after the four weeks of treatment.
” We discovered motivating outcomes,” Halpert said. “9 of the 10 dogs on CBD revealed advantages, which remained for 2 weeks after the treatment stopped. We did not find alterations in the blood markers we determined, suggesting that, under the conditions of our study, the treatment seems to be safe.”.
Chris D. Verrico et al, A randomized, double-blind, placebo-controlled research study of everyday cannabidiol for the treatment of canine osteoarthritis discomfort, Pain(2020). DOI: 10.1097/ j.pain.0000000000001896
Researchers discover CBD enhances arthritis symptoms in pets (2020, May 28).
retrieved 29 May2020
from https://phys.org/news/2020-05- cbd-arthritis-symptoms-dogs. html.
This file is subject to copyright. Apart from any reasonable dealing for the function of personal study or research study, no.
part might be recreated without the written approval. The material is provided for information functions only.
Austin Soldner and Michael Schaecher, the co-founders of the new sunglasses brand Futuremood, met at the newly formed San Francisco research and development lab created by the high-end audio tech developer Bose.
The two were tasked with working on Bose’s sunglasses wearable and bonded over a shared interest in sneakers and fashion. Over many conversations the two men realized there was an opportunity to use technology to rewrite the sunglasses playbook and launch the first new brand to the market since Oakley came on the scene.
There was also an opportunity to bring the materials science and tech-forward strategies that sneaker companies have developed to an industry that hadn’t seen any real technical revolutions in decades.
Enter Futuremood “Auras,” which the company bills as the first glasses scientifically tested and proven to alter your mood.
Using technology developed by the lens manufacturer Zeiss, Futuremood’s first glasses come in four colors — a relaxing green, a refreshing blue, an energizing red and a focusing yellow. The company is launching its eyewear in two styles, a boxy, chunky frame and a more traditional rounded frame.
Any mood-altering effects are thanks to Zeiss’ halochrome lens technology, which the lens manufacturer has been working with — and publishing papers on — to suss out the science behind its claims that the use of filtered light can change the way folks feel.
There’s some preliminary research that the company has done, but the science is still largely unproven (Zeiss conducted two studies at European universities).
Schaecher and Soldner are believers, and the two longtime tech execs see these lenses as a window into a wider world of material science experimentation and product development that they’re hoping to bring to market with Futuremood.
“If you think about sneakers and where Nike and Adidas got to where they are today, it was through innovation in product design and materials and branding and marketing and all of that had been missing from the sunglasses space,” Schaecher said.
The second marketing hire at Airbnb and the first marketing hire at the now-defunct Munchery, Schaecher knows a thing or two about branding. Meanwhile, Soldner, the founder of Playground.fm, and a former product designer at Jawbone, is the technical expert and lead designer for all of Futuremood’s frames.
“We really saw an opportunity to push the envelope in technical innovation and product innovation,” said Schaecher. “We have a backlog of stuff to push the envelope of what sunglasses are.”
One thing sunglasses are is a very very big business. Consumers spent $14.5 billion on sunglasses in 2018, according to the market research firm, Grand View Research.
If Futuremood can capture even a fraction of that market with its unique spin on sunglasses, it’ll be in good shape.
As with any good direct to consumer product, Futuremood’s difference begins with its packaging. Tapping in to the mood-altering “wearable drugs” aesthetic, the company’s product is packaged in boxes with the same bright hues as the sunglasses. Inside there’s a cloth to clean the glasses, a velvet pouch to hold them and a scented pack of incense matches and a vaguely tarot-esque card with information about the glasses and the sensation they’re meant to evoke (there’s even a Spotify playlist to listen to).
In an email, Schaecher described the sensation as “not as subtle as CBD, but not as strong as a shot of tequila or glass of Rosé.
“Austin and I are really into different ways of self care and taking moments and… we thought there was an opportunity to bring delight and joy,” with the packaging, Schaecher said. “We don’t expect people to be firing up Spotify playlists and incense matches every time they wear things.”
Futuremood has been mostly bootstrapped to date, and like everything else in the year of our Lord 2020, the company’s plans were pushed back by the coronavirus pandemic.
“Our lenses are made in Zeiss’ Italian factory and the glasses were made outside of Shenzhen,” said Schaecher. “We quarantined the first order for two weeks. Zeiss was right in that region of Italy that was getting hit hard. We’ve been delaying since then. It’s hard to put into words what it’s like to grind on something for eighteen months… and then have to delay launching.”
Even with the pandemic, though, the company moved ahead with the design for its second product, and that gives a hint for where Schaecher and Soldner want to go with their business. “We have our second product line and that is not mood-altering glasses,” said Schaecher. “That’s a traditional sunglasses line that uses titanium alloy metals that are more commonly seen in aerospace than in eyewear.”
The design aesthetic is also more in the luxury vein, which Schaecher teased was akin to something that would be more at home in a Cartier showroom rather than a direct to consumer brand’s digital storefront.
Right now, the company is going direct to consumers through its website, but it’s looking at the potential for some retail collaborations and field marketing when the country opens back up for business.
As for the mood-altering effects and whether “wearable drug” can win market share, Schaecher is pretty optimistic. “People definitely have reactions,” he said. “It’s a fun, new thing that’s never existed before.”
Boing invites Real Checked CBD as a sponsor!
Real Evaluated CBD is known for efforts in bringing info about the CBD products for not just established brand names, however the budding brands in the niche. We fuel our enthusiasm through the enthusiasm of our customers, asking us for updates on what is taking place in the CBD universe. Thanks to the laws in the United States that enable legal production of CBD items for health and research study, there are some premier items on the marketplace, however it is essential to understand what you are buying to guarantee the very best purchase.
We at Genuine Checked CBD run all the items through laboratory tests and present everything in black and white for our readers. Today, we review Charlotte’s Web and its CBD items that consist of balms, creams, tincture, edibles, and pills.
Here is a review of all the 9 products of Charlotte’s Web that we evaluated.
This hemp-infused balm by Charlotte’s web comes with 150 mg of botanical blend hemp extract. It has a soothing fragrance, and we found no traces of pesticides and solvents in the mix. Moreover, it contains all the goodness of CBD at 107.2 mg per pack. It also consists of THC at 4.69 mg and CBC at 4.48 mg per package. Our test results suggest that the overall CBD levels were lower than those claimed on the label.
This Canine hemp-infused balm is for adult pets with 450 mg of hemp extract. Our test results reveal the CBD levels are half the quantity of what the label claims. It does contain a decent CBD quantity still along with other helpful cannabinoids. The CBC and THC levels are at 8.67 mg and 5.53 mg per bundle; whereas, CBD levels are at 224.28 mg per package with no indication of pesticides or solvents.
This hemp-infused skin cream features 750 mg of hemp extract. It does consist of some CBD goodness, but our test results indicate these levels to be lower than the label’s claims. It has 19.1 mg of CBC and 14.63 mg of THC, which can be extremely beneficial to unwind. Plus, there is 328.74 of CBD crammed in this product.
Wow, this CBD isolate tincture by Charlotte’s web is one of our favorites. It delivers 20 mg of CBD per drop, and our test results suggest that this tincture contains more CBD than the label claims, which is a good idea as it increases the effectiveness of this item. The CBD levels are a tremendous 782.81 mg per package. There are no traces of any other cannabinoids in the cast, and there are no solvents or pesticides.
This Web Hemp extract tincture is an outstanding CBD product that is real to its label claims. It offers 12 mg of pure CBD extract that uses other useful cannabinoids present in natural hemp extract utilized in this item. The overall amount of CBD per bundle is 533.8 mg, with no trace of pesticides or solvents.
Our laboratory tests found an acceptable variety of CBD per container at below 25%. It appears to be full-spectrum CBD and includes CBC and THC in the mix, which makes it area on with its whole hemp extract claim. The CBD, THC, and CBC amounts are at449
Boing proudly invites EST as a sponsor. This […]
https://www.youtube.com/watch?v=-sQGbtjBMX4 Boing is happily sponsored by Privacy Safe! Pre-order now to take advantage of early-bird prices and get discounts on other privacy-respecting services and open hardware. Cutting […]
Boing is happily sponsored by Sugar and Kush! Click to Jump to a Section: Unhealthy CBD products Uncontrolled CBD Industry Pure Unflavored CBD Oil Best Carrier Oils for Bioavailability Laura Brenner & Sugar & Kush CBD Conclusion Cannabidiol, or CBD, is one of the numerous cannabinoids discovered in the marijuana plant. Unlike the more […]
” Live as if you were to pass away tomorrow. Learn as if you were to live permanently”– Mahatma Gandhi Of all the skills you feel like you should probably understand, yet most likely do not, coding might be one of the most intimidating. From the diverse programming languages to the range of platforms to the sheer discomfort […]
Even though it seems like Amazon is a particular retail juggernaut squashing everybody else, you may be surprised to find out that half of Amazon’s $280 billion in revenue in 2015 originated from third-party sellers. According to numbers compiled by JungleScout, 86 percent of Amazon’s Fulfilled by Amazon (FBA) sellers were profitable last year, more than […]
Amidst all the lethal major concern and fallout from our global battle against COVID-19, you’ve likely been forced to challenge more than a few moments that you never ever anticipated to deal with. And you likely never ever felt sillier throughout this frightening time than when you were racing all over town hoping frantically that some shop had […]
Throughout nearly a week, Aurora Marijuana( ACB) has surged more than 200%from the reverse split lows near $5 prior to the strong FQ3 report My financial investment thesis was very bullish after the transformational quarter and favorable potential customers for reaching EBITDA favorable in the September quarter, but the stock rally to more than $17 on a small U.S. CBD acquisition is too far, too quick.
U.S. CBD Offer
After the close on Wednesday, Aurora Marijuana announced a deal to go into the U.S. CBD market with the purchase of Reliva for $40 million in stock with an extra earn-out capacity of another $45 million in cash or stock. The offer is adjusted EBITDA accretive essentially due to the fact that the business is EBITDA favorable and Aurora Cannabis is still producing large EBITDA losses.
Reliva obviously has an earnings base of $14 million, making the deal fairly small in contrast to Aurora Cannabis, which is on a path towards incomes of $300 million in FY21 ending in June. Also, the offer pulls Aurora Marijuana into the U.S. market with the included complexities of operating a recreational marijuana service in Canada and international medical marijuana in numerous worldwide nations on top of this new endeavor.
The deal likewise immerses Aurora Marijuana into a highly competitive U.S. CBD market where market leader Charlotte’s Web Holdings( OTCQX: CWBHF) has had a hard time. The company saw Q1 revenues decline 1% to $215 million due to the FDA constraints.
Reliva has access to 20,000 retail places in the U.S. and is ranked as the No. 1 CBD player in topicals. Unfortunately, the item classification dominated by this company isn’t the one reduced by the FDA guidelines which restricts the sale of hemp-infused CBD in dietary supplements causing the weak point at CWH.
In addition, purchasing Reliva does not enable Aurora Cannabis to enter the medical or leisure cannabis market. The federal government still needs to approve marijuana for a company listed on the major stock market to get in those markets and the business will have to buy their way into inflated stock valuations in the future.
Aurora Marijuana is making a sensible move to swoop into the U.S. market with a little preliminary purchase in a land and broaden relocation. The company does not have a great deal of money at risk here by entering a highly-competitive market with getting a prospective rival when getting in the market with their own brand.
Unfortunately for financiers, the stock has actually soared off the $5.30 lows prior to the FQ3 revenues report. Aurora Marijuana is now up to $1740 With 109 million shares heading into the this deal and ~112 million after the stock deal, Aurora Marijuana now all of a sudden has a market cap of $1.95 billion.
Aurora Marijuana still has a ton of cost cuts to carry out while maintaining some moderate earnings growth in order to reach EBITDA favorable in Q1’21 The company is still targeting lowering business expenses to the C$45 million variety while analysts have earnings growing sequentially in the next few quarters. Attaining this objective isn’t an assurance as the business cuts operating costs by 50%over the course of a couple of months. The majority of business run into unexpected missteps when eliminating staff members.
The Canadian marijuana stocks are usually more costly than the U.S. multi-state operators. Both Aurora Cannabis and Canopy Development( CGC) trade around an EV/S multiple of 6x while the U.S. MSOs of Curaleaf( OTCPK: CURLF) and Trulieve Marijuana( OTCQX: TCNNF) trade at half the multiples at listed below 3x.
Aurora Cannabis is still pursuing an aggressive goal of cutting a C$509 million EBITDA loss from the March quarter into positive EBITDA in the September quarter. Curaleaf just printed a March quarter with a $200 million EBITDA revenue while Trulieve Cannabis generated an excellent $494 million EBITDA revenue
The drastic distinctions in the revenue pictures favor the MSOs after the rally in Aurora Cannabis. The Canadian marijuana business is improving, but the marketplace has become too bullish on the turnaround and the move into the competitive U.S. CBD sector.
The key investor takeaway is that Aurora Cannabis is making smarter corporate relocations in 2020, but the stock tripling off the bottom pleads for a pullback. The stock is pricey relative to other marijuana stocks over $17 here.
Investors wanting to play the turnaround in Aurora Marijuana should wait for a dip back to $10 where much better value will emerge and the risks show the trouble of the Canadian cannabis company attaining EBITDA positive numbers.
Searching for a portfolio of ideas like this one? Members of DIY Worth Investing get special access to our model portfolios plus a lot more. Signup today to see the stocks bought by my Out Fox model throughout this market crash.
I have no business relationship with any business whose stock is pointed out in this post.
Extra disclosure: The info included herein is for informational functions only. Absolutely nothing in this article must be taken as a solicitation to acquire or sell securities. Before buying or offering any stock you need to do your own research study and reach your own conclusion or speak with a monetary advisor. Investing consists of threats, including loss of principal.
“Cannabis Treats COVID-19” Rallied Weed Stocks. Cannabis Could Aid Pandemic—If Someone Pays To Find Out.
Already down when the coronavirus pandemic kicked all markets, a few cannabis stocks enjoyed rallies Friday — gains connected, it would seem, to the coronavirus pandemic.
Colorado’s CBD giant Charlotte’s Web, named for pediatric cannabis patient Charlotte Figi, who died last month of complications from the coronavirus, was up 24 percent on the Toronto Stock Exchange. But the big gain was on NASDAQ, where shares in Canadian firm Sundial spiked 50 percent—a jump, to $0.83 a share, that’s nothing close to wiping out last year’s losses, but nonetheless a very big rally in context.
And a rally “vaguely” timed, as MarketWatch reporter Max Cherney observed, with the New York Post’s publication Thursday of its take on the big story that had gone viral on Facebook earlier that month, and was later flagged as fake news: the claim, first made in a preclinical paper published in April, by Canadian scientists that certain high CBD strains of “cannabis could prevent and treat coronavirus.”
Cannabis and COVID together strikes a nerve, already: since the beginning of the pandemic, unscrupulous cannabis companies have been claiming, without any data, that their products might manage COVID symptoms or even act as a preventative. But this wasn’t that, as researchers at the University of Lethbridge explained in interviews with the Calgary Herald and CTV, recycled by the Post.
In experiments with 3D human cell cultures mimicking various diseases, certain high CBD cannabis strains—developed by the researchers labs, in no relation to the cannabis available in legal and recreational markets in Canada or the US—demonstrated abilities to shut down coronavirus’s favorite “pathway: a receptor called ACE2.
Rife in lung cells but also present in the mouth and gut, ACE2 regulates the virus’s ability to enter cells and replicate. One of the Lethbridge CBD strains downregulated the ACE2 receptor in certain 3D cells by as much as 73 percent, according to Lethbridge biological scientist and study lead author Igor Kovalchuk. This is a reason why the ACE2 receptor, and turning it off, is the target of pharmaceutical interventions like experimental novel coronavirus vaccines—and this is why a consumer product that contains one of the Lethbridge-grown cannabis strains might be a useful supplemental therapy for COVID-19 patients. Perhaps in a mouthwash, the preclinical paper suggested.
None of this means cannabis is a COVID-19 cure, or a COVID-19 prevention—just, maybe, a COVID-19 treatment. That didn’t stop certain media outlets, including one weed publication called out by name by The Poynter Institute’s Politifact in a May 18 item, from running items “overstating” the Lethbridge scientists’ findings, as Kovalcuk himself admitted. But the Post got it right.
“It reduces the possibility to get infected. I never said it would prevent or block it entirely,” he said in a telephone interview over the weekend.
“It is a possible treatment,” he added. ‘A treatment is not a cure. When [news reports] say it treats COVID, or can potentially treat COVID, they are absolutely right.”
For Kovalchuk’s research team, the coronavirus pandemic struck at an auspicious time. Kovalchuk runs a company called Pathway Rx. Pathway is a Sundial subsidiary—a fact not mentioned in the Post—and earlier this year, after the company’s fortunes had plummeted from summertime trading of $12 a share to this winter’s sub-$1 nadir, his team’s research was close to getting shut down for lack of money.
When COVID appeared, “I thought, well, it’s a virus, it’s inflammation, there must be something cannabis does,” Kovalchuk recalled. So his team dived back into the models. And since COVID-19 attacks the ACE2 receptor, a receptor his strains seem to block, “the rest is history.”
As for the temporary market gains, “I don’t really care,” Kovalchuk insisted. “I want this to be brought to people. And that can only be done once a clinical trial is done.”
The trick now is to convince an investor—be it a cannabis company or anyone else—to pay for study that involves humans. This will require even more money.
For around $700,000 US, Kovalchuk believes he could enroll several hundred human volunteers — COVID-19 patients willing to supplement their doctor-prescribed regimen with a Pathway Rx cannabis product, to see if their recoveries were quicker or their symptoms less severe than a control group’s. If hospitalization stays, length of illness, and other indicators among the experimental group dropped by 20 percent compared to control, more study and a larger cohort would be required. If it were 50 percent—then maybe we’d have an accepted additional therapy.
For now, the main takeaway is that “cannabis,” meaning the stash in your jar, or the stash available at the dispensary, or the CBD oil flogged online, isn’t going to do anything. Pressed for details about terpene notes or full cannabinoind spectrum information about his special strains, Kovalchuk stayed mum. But he did emphasize that it’s very likely the full spectrum of terpenes and cannabinoids, not just the high-CBD/low-THC ratio, that’s finding success inhibiting the ACE2 receptor favored by the coronavirus.
“It’s very important that it’s not just generic CBD,” he added. “You just can’t go anywhere and get CBD [that will work on COVID-19]. That’s why we’re afraid of people just rushing out to start buying it.”
Which, apparently, people have done—and not just CBD, but CBD stocks, too.
So you think the cannabis sector has seen its worst? That there’s no coming back? Well, here’s a twist: The COVID-19 pandemic might have dragged down most sectors, but it is lifting up marijuana stocks for sure. Cannabis sales skyrocketed in April amid the pandemic, pushing companies’ revenues higher. In fact, most marijuana businesses reported good revenue numbers this quarter. But one, in particular, seems to have risen from the dead.
A phoenix from the ashes
Edmonton, Alberta-based Aurora Cannabis (NYSE:ACB) saw strong demand after Canada legalized recreational marijuana in 2018. The company ramped up its production facilities, paying little attention to its rising debt. External factors including black-market sales and a slow rollout of stores post-legalization made it harder for the company to make a profit; ultimately, investors lost trust, and the stock kept sinking below $1 — to the point that it was at risk of being delisted from the New York Stock Exchange.
Image Source: Getty Images.
In May, however, Aurora seems to have risen from the dead. To save its stock and strengthen its cash position, it consolidated its shares in a 1-for-12 reverse stock split. Surprisingly, its third-quarter results were a hit. The company recorded year-over-year revenue growth of 16%, to 75.5 million Canadian dollars. It also reported sequential quarterly sales growth of 35%.
Its Q3 consumer cannabis revenue was up 24% sequentially to CA$41.5 million; that included its Daily Special brand, launched in February, and a few of the cannabis 2.0 products, launched in December. Medical cannabis revenue also increased by 13.5% sequentially. Management said they didn’t see much impact from Covid-19 in the third quarter, but they do expect it in Q4.
Despite a good quarter, it’s smart to be skeptical. Q3 results can’t hide the fact that despite rising revenues, Aurora reported negative EBITDA (earnings before interest, taxes, depreciation, and amortization) of CA$50.8 million in Q3. Selling, general, and administrative (SG&A) expenses in the third quarter came in at CA$75 million. Management assured investors that Aurora is working to reduce SG&A and hit positive EBITDA by Q1 2021, but analysts remain skeptical.
Making it more exciting: A strategic acquisition in the U.S. CBD market
Aurora Cannabis is marking its entry into the U.S. cannabidiol (CBD) market with the acquisition of hemp-derived CBD company Reliva. The deal will leave Reliva’s shareholders with $40 million worth of Aurora’s shares, and that number could rise to $45 million over the next two years if Reliva achieves certain financial targets. The transaction will close by June.
What worries me is that Aurora might be reliving its past mistakes. Not even a month ago, it was drowning in debt, and now it’s making acquisitions? Don’t get me wrong; the U.S. CBD market is a rising star. It’s just that these products still face doubts from the U.S. Food and Drug Administration (FDA), which seems hesitant about the use and marketing of CBD products in the U.S.
That said, striking a deal with a company that has no debt and a strong market position in the U.S. — Reliva boasts 20,000 retail stores — could prove to be a wise move. Reliva also generated positive EBITDA over the past 12 months, ending in March. Reliva’s U.S. management team will be part of Aurora, and that might just help the latter company, given that its current leadership team has proven questionable.
Recently, Canopy Growth (NYSE:CGC) also announced the launch of its next batch of cannabis 2.0 products — cannabis-infused beverages, chocolates, and vapes. Canopy Growth, along with its partner, Constellation Brands (NYSE:STZ), expects to capture a new range of customers with its innovative products.
Achieving profitability is what matters
Shares of Aurora and Canopy are up 106% and 16%, respectively, so far in May, while the SPDR S&P 500 ETF (NYSEMKT:SPY) has declined by 4.1%.
The stock volatility could drag on with the market uncertainty around the pandemic. What matters to cannabis investors is whether Aurora can sustain its promises, manage to reduce expenses, and hit profitability within the stated time frame. Aurora’s entry into the U.S. CBD space and its innovative cannabis 2.0 products present a good opportunity for the company to recover in 2020.
Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands. The Motley Fool has a disclosure policy.”>
Aurora Marijuana( NYSE: ACB) lastly made the move that investors have actually anxiously awaited for a long period of time. The Canadian cannabis manufacturer announced recently that it entered into an agreement to purchase Reliva, which boasts among the top-selling CBD brands in the U.S. market.
Financiers cheered the news that Aurora will quickly be able to delve into the big U.S. CBD market. Several of the company’s top competitors, consisting of Canopy Growth and Cronos Group, currently have a presence in the U.S.
Aurora mentioned that Reliva is “rewarding today” and will provide the company with a leading hemp CBD brand that’s currently sold in more than 20,000 retail locations in the U.S. Don’t believe Aurora Cannabis’ success spin.
Image source: Getty Images.
Reliva is privately held, so there aren’t public documents available that supply information on the company’s monetary efficiency. Aurora Cannabis interim CEO Michael Singer shared some intriguing info in an interview with MarketWatch last week.
This represents just a fraction of Aurora’s yearly sales. Reliva could really well end up being a significant growth driver for Aurora.
The more eyebrow-raising thing that Singer stated is that Reliva isn’t rewarding on a GAAP basis, the accounting standard by which U.S. business report their financial outcomes. Instead, the little CBD company has actually just produced earnings on an adjusted basis.
Often, adjusted earnings give investors a more precise photo of how well a business is carrying out. For instance, one-time expenses that don’t affect a business’s continuous performance can be factored out. Nevertheless, it’s impossible to know today all of the adjustments that Reliva makes to be able to report its “success.” A few of those adjustments might not be as defensible as one-time expenses.
The bottom line is that we actually do not know how Reliva’s real bottom line looks. What we do understand is that Aurora’s news release announcing the acquisition mentioned that Reliva paid (with no caveats or information) and that it took a follow-up interview for investors to learn the rest of the story.
It’s not unexpected that Aurora would refer to an adjusted financial number as being profitable. The company’s executives regularly do it when they go over Aurora’s monetary future.
For instance, Singer spoke about the company’s cost-cutting moves in his remarks during Aurora’s Q3 teleconference earlier this month He specified that these moves will “fuel profitability” for Aurora. Anytime Aurora’s management group mentions profitability, they’re actually implying changed EBITDA profitability.
If you’re not familiar with EBITDA, the term stands for revenues before interest, taxes, depreciation, and amortization. Generating positive EBITDA is an excellent thing, especially for Aurora, which posted negative adjusted EBITDA of 50.9 million in Canadian dollars in the third quarter.
Aurora believes that it will be able to deliver positive adjusted EBITDA by the first quarter of financial 2021, which ends on Sept. 30,2020 And while Aurora has benefited from tax recoveries in the existing financial year, at some point paying taxes will negatively affect its financial outcomes.
Note likewise that the word “adjusted” is still being utilized. Unlike the scenario with Reliva, however, we have a respectable concept of which changes Aurora can take with its EBITDA figure due to the fact that the regards to its monetary covenants for its debt facility spell them out.
Beyond the spin
Fortunately for Aurora is that it appears to be making strong development toward its goal of producing positive adjusted EBITDA by the end of September. The company’s acquisition of Reliva should also be favorable over the long run as the U.S. CBD market grows.
Nevertheless, there are still considerable challenges for Aurora. It remains to be seen how rapidly the Canadian market will rebound as limitations related to the COVID-19 pandemic are relaxed. The cannabis stock could quit much of its recent gains with any bumps in the road.
Most significantly, Aurora could have to go to the well yet once again to raise extra money through another dilution-causing stock offering or attempt to take on even more debt. And what Aurora calls profitability isn’t true profitability.
On a typical Saturday, at 4: 30 am, Boulder, Colorado-based competitive ultramarathoner Flavie Dokken takes 5mg of Wana Recreational Tarts, places on her running shoes, and navigates a five-hour run. Dokken is not your common stoner, she utilizes cannabis as part of her exercise regular and she is sponsored by Wana Brands, a cannabis business that produces cannabis-infused products. Dokken informed Vice that the gummies help her tune into her breathing. Dokken utilizes THC (tetrahydrocannabinol, the psychedelic component of marijuana) throughout training, she stops using it a week prior to race day since of drug testing.
” Active way of life” may not be a set of words commonly associated with cannabis usage. But marijuana business are trying to change that by sponsoring athletes and athletic groups, getting them to post pictures of items on their Instagram grids or put brand sticker labels on their athletic devices, in order to get presence with the professional athletes’ fans.
Brands like Nike, Saucony, and New Balance, associated with the running industry, do not permit their athletes to be connected with marijuana. But that does not indicate they never partake. Dokken said she knows of a handful who do. Not just are they secretive about their use, but they likewise avoid connecting with her for worry of guilt by association. She said that these athletes, “won’t follow me on Instagram,” but she likewise mentions that when she wears her Wana gear on the routes in Colorado, “individuals give me a high-five, which is incredible.”
Even as big brand names don’t wish to speak about cannabis usage, it is progressively formally sanctioned for competitive professional and amateur professional athletes: In 2018, the World Anti-Doping Firm (WADA) Code got rid of CBD from their list of prohibited substances, and permits a professional athlete to have THC in their system throughout a random out-of-competition drug test. However THC is still a prohibited compound for post-race or in-competition drug tests; this all means professional athletes are fine to use marijuana during the off-season and even during training, however can not compete with the drug in their system.
In 2018, Canada legalized cannabis with the Cannabis Act, which restricts athletes from being sponsored by marijuana companies. Canadian Mixed Martial Arts fighter Elias Theodorou is trying to change that. He utilizes marijuana for pain management for bilateral neuropathy in his upper extremities (chronic pain in his wrists, elbows, upper neck, and spinal column). “Doctor prescribed marijuana is the best medical alternative to handle my discomfort,” he told VICE. “Conventional, first-line medications like pain reliever, opioids, and NSAIDs have all had detrimental side-effects to my body as both a patient and athlete.”
Theodorou, who has been sponsored by Pert Plus, Mattel, and Coors Light, described, “This fight is not just about working with marijuana companies, but likewise the need to knock down the barriers and unfavorable perception other companies might have with marijuana.”
Mendi, a CBD start-up company, has “professional athlete ambassadors” who assist promote their products, including soccer player and Women’s World Cup winner Megan Rapinoe, and her sweetheart, WNBA gamer Sue Bird. The athlete ambassadors receive Mendi items to promote on their social channels and attend Mendi occasions. The business was founded by Rapinoe’s twin sibling, Rachael, who is likewise a previous pro soccer gamer. CBD is prohibited in the WNBA, Bird uses it in her off-season. She informed New York City Magazine, “It’s fantastic for recovery and it relaxes me. I usually take it at night so I can sleep, which assists with recovery, and have actually had incredible results.”
While the use of cannabis might appear diametrically opposed to what a professional athlete worths– inactiveness versus action– calm, relaxation, and rest are essential to professional athletes’ total success and well-being. But professional athletes don’t even restrict use to off-hours in our contemporary times: In 2019, The University of Colorado Stone launched a study on over 600 runners with legalized cannabis that discovered 80 percent of cannabis users blended workouts with marijuana use. Although cannabis is not a performance-enhancing drug, Dr. Rosemary Mazanet, Chief Scientific Officer of Columbia Care, claimed to VICE it can assist decrease performance anxiety. “You have the ability to be more in the minute and have more fun, to be more limber, to be more versatile,” said Manazet.
Pulmonologist Vandana A. Patel stressed to VICE by means of email that cigarette smoking marijuana can negatively impact a professional athlete’s efficiency. “Inhaling marijuana can trigger structural lung injuries, like building air pockets in the lung which can burst under increased physical stress.” Due to the fact that of this, many professional athletes, like Dokken, stick to edibles.
The owners of the Oregon-based dispensary Tokyo Starfish all previously operated in the snowboarding industry prior to they transitioned into opening a dispensary. Tokyo Starfish-sponsored expert snowboarder, Max Warbington explained that the dispensary concentrates on the way of life element of snowboarding rather than the efficiency element.
Tokyo Starfish-sponsored snowboarder Nora Beck informed VICE that she uses cannabis throughout snowboarding when she requires to unwind. She discusses, “It resembles you’re on hyperdrive and you just require to turn the volume down a bit.”
” Tokyo Starfish is actually bought snowboarding and they understand that I’m out there doing my task as a pro snowboarder and just the truth that I have the Tokyo sticker that resembles an overall benefit for them,” Warbington said. As a professional snowboarder sponsored by Tokyo Starfish, Warbington sends out the company videos and images throughout the winter. He also wears their Tee shirts and hoodies and markets them to snowboarding fans on his social networks.
When asked whether he feels like there’s a stigma as an athlete sponsored by a cannabis business, he responded, “I believe they’re most likely always will be [a stigma] just the same as there’s a preconception with alcohol due to the fact that it’s a compound that individuals abuse.”
In a phone interview with VICE, Warbington stated he is especially conscious of his image. “I absolutely don’t want to press it [cannabis] on the youth which’s why I constantly like to preach that.” He does not permit Tokyo Starfish to post images on their social media of him smoking pot, though Warbington often publishes a picture of a joint in his personal Instagram stories. He stated, “I constantly second-guess it whenever due to the fact that of my influence.”
Brands like Tokyo Starfish and Wana are trying to fight negative associations with cannabis. They want the general public to affiliate the recreational drug with an active way of life. Warbington stated it’s truly essential to him that people know he and his Tokyo Starfish teammates do not personify the “lazy stoner” stereotype. Far from it. “We’re out here smoking weed,” he stated. “We’re the very first individual up [on the slopes in the morning] and the last one to leave the mountain.”
Cosmetics brand taps into two major trends expected to continue after Covid-19
e.l.f.’s Chipotle-inspired makeup kit sold out in 4 minutes (though supply was limited).
A new Chipotle-inspired prom makeup kit by e.l.f. Cosmetics is the result of an unusual but clever mashup with the fast-casual chain, and sold out in mere minutes Thursday, CMO Kory Marchisotto told Adweek.
The cosmetics and skincare company also launched a line of full-spectrum CBD skincare products this week to appeal to shoppers’ heightened desire for skincare and wellness products during the pandemic, she added.
The collaboration and the new offerings are the latest examples of how brands are coming up with inventive ways to boost business in a difficult time.
“E.l.f. and Chipotle go together because our values align,” said Marchisotto, adding that such efforts also fulfill the company’s desire to put a smile on people’s faces during a difficult time.
The mission of e.l.f. is to make beauty accessible to every eye, lip and face, while Chipotle’s aim is to make better food accessible to everyone, she noted.
“Like Chipotle’s commitment to responsibly sourced food, e.l.f. prides itself on 100% vegan products, and the parallels certainly don’t end there. Both brands are quick-thinking, agile disruptors who can move fast on ideas that resonate with the Gen Z audience,” said Tressie Lieberman, vp of digital and off-premise marketing at Chipotle.
While brand mashups are not new, they will likely gain traction as consumers seek unique products and experiences that stand out from the crowd.
The offering is part of a broader collaboration between the cosmetics brand and Chipotle, which is hosting a virtual prom afterparty Friday evening following Teen Vogue’s virtual prom event.
The kit includes a silver pouch that resembles a wrapped burrito, while the makeup includes a primer-infused brush as a stand-in for guac, a lip exfoliator called Brown Sugar in lieu of brown rice, and a putty primer matte in place of sour cream.
In addition to the partnership, e.l.f. is recalibrating its product lineup to include more skincare and health and wellness products, as demand for those items has spiked during the pandemic.
In particular, the company launched a line of full-spectrum CBD products, which have trace amounts of THC, including a facial oil, an eye cream, a body cream and a moisturizer.
The CBD line caters to consumers’ need for a moment of calm and self-care, especially in this anxiety-ridden moment for the world, Marchisotto said. “What we see now is a blurring between wellness and beauty,” she said.
It’s also part of e.l.f.’s culture of testing and learning. “We have a high risk tolerance,” she said. It comes from the original founders’ desire to sell a premium product for $1 over the internet some 16 years ago, and against the odds, succeeding. “They made the impossible possible,” Marchisotto said.
Like with TikTok, which e.l.f. has had a presence on since the platform’s early days, the cosmetics company doesn’t overthink—it tests and repeats what’s successful, Marchisotto explained.
For example, the beauty brand issued a hashtag challenge featuring an original song on TikTok to test the platform and measure customer engagement, which as of May 10 resulted in the creation of 3.5 million videos and generated 5.2 billion views.
In another example, the full-spectrum CBD line builds on the successful introduction of cannabis sativa-infused products late last year such as Happy Hydration Cream, Calm Balm lip balm and Puff Puff Primer.
Being first to market with innovative products is one of the things e.l.f. prides itself on, Marchisotto said. “One of things e.l.f. does brilliantly is we build on demands we hear, sentiment we hear.”
Editor’s note: This article was updated to reflect the latest numbers for e.l.f.’s TikTok hashtag challenge, which resulted in the creation of 3.5 million videos and 5.2 billion views.
Warren Bobrow=WB: Please inform me where you are from? Where are you now? What did you wish to be when you (grew) up? Do you have a coach? Who is that?
Justin Johnson=JJ: I grew up in Washington state, spending the majority of my youth in Spokane, which is pretty rural, a lot closer to Idaho and Montana than Seattle.
Consumed with TV commercials from an early age, I attended Washington State University with the goal of ending up being an imaginative director at a New York advertising agency. That was the dream. I excelled academically in high school and at the next level, but college is where I likewise began to establish a deeper gratitude for marijuana, which I utilized frequently to manage anxiety from undiagnosed Compulsive Disorder.
After finishing top of my class, I presumed no firm could resist me and attempted a transfer to New york city with my best friend to pursue the dream. It resulted in a week of travelling in between Manhattan and Dobbs Ferryboat, where we slept head to toe on a mattress in a corridor, just to interview for tasks with salaries below the poverty line. Dejected, we both agreed the New york city dream would need to come later in life.
I ultimately wound up in Seattle, where I landed a task at WONGDOODY, a highly decorated imaginative company I admired in college. While my goal was constantly to be a “creative,” my mix of writing ability, tactical thinking, and digital savvy got me quickly acknowledged by Michael Hoffman, our head of business advancement and one of my earliest coaches.
In a previous life, Michael was accountable for the launch of a little tennis shoe called the Air Jordan 1 with then rookie Michael Jordan and a reasonably unknown Spike Lee. Michael Hoffman himself didn’t stand much taller than 5 feet, however he was a giant to me. He died in 2015, however I was quite lucky to have him as a manager and good example. He set the structure for much of my expert success, teaching me how to lead with enthusiasm, empathy, and a dedication to excellence. He also taught that mentorship was a two way road, and that I had a lot to provide.
Within a couple years under Michael I was promoted to handle company advancement for our workplace in Los Angeles, where my appreciation for marijuana blossomed, and social media started to wreak havoc on the conventional firm design. As TV ad spending plans dried up in 2008, my function altered from pursuing new organisation to developing expertise in brand-new services like web analytics, search engine optimization, social content production, and early models of Facebook and Google advertising that control budget plans today.
I ultimately left WONGDOODY in 2011 to sign up with Lunchbox, where I ‘d manage online home entertainment initiatives in between Walmart and Unilever, varying from branded music videos with Slash to interviews with Kevin Hart about his brand-new funny special.
Today I invest my days structure BudsFeed, advocating for the rights of cannabis customers, and consulting brands and start-ups. My other half and I call Brooklyn home, but began investing in upstate AirBnB’s about three years back. We just finished remodeling a cabin in Wassaic, NY at the beginning of 2020 and have been living up here since the virus hit.
WB: Please tell me about your company? What is your six and twelve-month goal? What barriers stand in your way? How do you prepare for removing them?
JJ: BudsFeed.com is a website that surfaces the finest brand-new marijuana associated items through the power of community.
Every Monday we celebrate the “Leading 5 Seeds,” based upon neighborhood upvotes, including those products throughout our site, newsletter, and social content. We likewise work with brands on more significant material cooperations, including blog posts, initial animations, item demonstration videos, and features in our original web series, “Buds Unboxing.”
We spent late 2019 and early 2020 focused on listening to early users, tweaking the experience, and structure functions that motivated engagement.
In the next 6 months, it’s everything about growth and continued improvement in the BudsFeed user experience. While our consumer audience continues to grow naturally every day, we intend to get more brands participating in the neighborhood and sharing brand-new item drops. Our company believe that market pioneers have actually constantly been at the forefront of cannabis culture, which is no different today. Whether we’re discussing flower, glass, or even industrial distillation equipment, brand names are driving development in the marijuana industry.
12 months from now, I hope that BudsFeed will be part of every cannabis-related brand name’s product launch technique.
The biggest barrier for BudsFeed right now is awareness, however that is something you can only change with a good technique and time or money.
WB: What about preconceptions? Do you run into them with standard service channels? How do you select your clients? Do you delight in marijuana? CBD? Entourage Result?
JJ: I have actually taken in marijuana nearly daily considering that I was 18- years-old, with a couple of length breaks in between.
Having spent more than a years at marketing agencies in Seattle, Los Angeles, and New York, I’ve surrounded myself with a lot of like-minded people when it comes to cannabis. Others have actually grown more far-off, feeling unpleasant having a public association with the marijuana market, but I think the preconception is fading quickly.
Among the most significant obstacles I’ve come across as a cannabis surrounding service– and I’m not alone– is a lack of quality paid advertising channels available. While I used to count Facebook, Instagram, Snapchat and other platforms as official partners of my agency, most make it near impossible to get cannabis-related ads approved. These platforms are losing out on hundreds of millions of marketing dollars each year due to blanket policies based on U.S. federal law, and it’s regrettable for both sides. Even 100%legal CBD brands have a hard time to successfully advertise.
What it comes down to is an absence of education at the greatest levels.
We hope BudsFeed can do its part to end the preconception and aid marijuana related brand names construct awareness, even when other social platforms will not.
WB: Do you prepare? What is your favorite thing to prepare?
JJ: I really enjoy cooking and invested most of my teenage years operating in dining establishments, where I discovered enough to be harmful in the kitchen area.
My preferred thing to cook is brunch. I feel like breakfast food is universally scrumptious and something I can make in mass for pals and family.
While I like cooking, I ‘d almost constantly prefer to dine out.
WB: What is your enthusiasm?
JJ: I’ve constantly been consumed with developing experiences that connect people, specifically online.
Going back to my youth, long before Giphy, I was always creating animated GIF sites that I would show other kids in chat rooms. Even into my mid 20’s I was consumed with platforms like Tumblr that permitted me to develop meme blogs that might amass a response from countless individuals over night.
Expertly I turned this enthusiasm and curiosity into producing digital home entertainment experiences for huge brand names, and became part of a great deal of firsts in social networks marketing. I learned a lot about building a brand name in the digital age from these experiences, and much more about the intersection of neighborhood, content, and innovation dealing with the similarity Facebook and YouTube.
Today I use that enthusiasm and all of my learnings into structure BudsFeed, a place I hope everybody can feel welcome connecting over a shared gratitude for cannabis-related products, services, and content.
For years, there was no hotter financial investment on earth than cannabis stocks With Canada legislating recreational marijuana in 2018 and 10s of billions of dollars in sales being conducted each year in the black market worldwide, the door seemed wide open for North American certified manufacturers to seize this chance and provide the green for financiers.
But over the past 13- plus months, investors have just seen a sea of red. Regulatory-based supply problems in Canada, stubbornly high tax rates in the U.S., and funding issues throughout The United States and Canada have actually haunted the industry and sent pot stock appraisals toppling
Image source: Getty Images.
Millennials’ preferred pot stock has been an eyesore
Perhaps the most significant dissatisfaction of all has been Aurora Marijuana( NYSE: ACB)
Aurora had actually also hired billionaire activist financier Nelson Peltz as a tactical advisor in March2019 Peltz’s location of know-how happens to be the food and beverage market, making him the best intermediary to work out a possible collaboration or equity financial investment in between Aurora and a brand-name business.
Unfortunately, little has actually gone Aurora’s way over the previous year and modification.
What’s more, Aurora’s worldwide sales have actually been specifically dismaying for investors. In spite of its noteworthy worldwide existence, Aurora managed a weak $4 million Canadian in overseas sales throughout the fiscal 3rd quarter (ended March 31, 2020) and hadn’t yet detailed its strategy to enter the potentially rewarding U.S. market– that is, until now.
Image source: Getty Images.
Aurora announces its strategy to enter the U.S.
Following the closing bell on Wednesday, May 20, Aurora revealed that it would get independently held hemp-derived cannabidiol (CBD) items business Reliva in an all-stock offer valued at $40 million (that’s U.S.). CBD is the nonpsychoactive cannabinoid best-known for its perceived medical advantages.
As a tip, marijuana isn’t federally legal in the United States. This means New York Stock Exchange-listed or Nasdaq– listed companies would risk delisting by operating in the U.S. pot industry. The Farm Costs, which was signed into law by President Trump in December 2018, gave the green light for the industrial production of hemp and hemp-derived CBD. Therefore, Canadian licensed producers do have the capability to enter the U.S. CBD market without breaching any federal laws. That is essential, since it allows Canadian certified producers to establish facilities on U.S. soil and create partnerships that might end up being worthwhile if and when the U.S. federal government legislates marijuana.
As you might remember, Aurora is required to create positive adjusted EBITDA by the end of the fiscal very first quarter of 2021 (ended Sept. 30, 2020) as part of its brand-new debt covenant.
According to the release, Reliva ranked No. 2 in total CBD market share, with item schedule in over 20,000 retail locations (that includes e-commerce). Reliva likewise has contracts with 40%of the top-20 nationwide convenience-store chains.
Presuming particular monetary targets are struck over the next 2 years, Reliva stakeholders can earn up to an additional $45 million in payments, which is payable in cash or typical stock.
Image source: Getty Images.
Do not break out the champagne right now
At the time of this writing, Aurora Marijuana’ shareholders were beyond delighted with this long-awaited relocation into the United States. Shares of the company, which performed a 1 for 12 reverse split last week, were up more than 32%to almost $17 a share in after-hours trading on Wednesday evening. However before you uncork the champagne and re-anoint Aurora as the greatest thing because sliced bread in the cannabis space, think about a few elements.
Initially off, Aurora has an actually bad track record when it comes to acquisitions.64 billion all-stock MedReleaf offer eventually got the company 35,000 kilos of yearly production and a handful of special brand names.
Second Of All, Aurora is, as soon as again, leaning on its common stock as a funding tool when buying. With the exception of the CanniMed offer, Aurora has nearly specifically count on growing its reach by releasing stock and diluting its long-lasting shareholders. Inclusive of its reverse split, the company’s impressive share count has actually ballooned from 1.3 million in June 2014 to more than 109 million today. The all-stock Reliva deal might add anywhere from 2%to 5%to the business’s exceptional share count, while a $350 million at-the-market offering has the prospective to increase the business’s exceptional share total by another 20%to 25%.
3rd, you must comprehend that the U.S. CBD market hasn’t delivered the jaw-dropping growth that was anticipated. Demand for CBD products continues to grow, the U.S. Food and Drug Administration (FDA) put its foot down on enabling CBD to be included to food, beverages, and dietary supplements. The FDA’s Nov. 25, 2019 consumer upgrade likewise warned customers that “CBD has the prospective to harm you.” Suffice it to state that the FDA’s objection to bend on this view without carrying out additional research has considerably reduced the glass ceiling on CBD’s U.S. sales capacity.
Logistically, getting in the U.S. CBD makes total sense for Aurora Cannabis. However the question its investors are constantly left questioning is, at what cost to them?
Sean Williams has no position in any of the stocks mentioned.”>
The Memorial Day sales have started early this year, and it’s simple to discover yourself drowning in offers for low-cost mattresses, devices, shoes, and grills.
Through May 31, you can conserve as much as $400 on every bed mattress model Leesa has to provide, from the value-minded Studio by Leesa design to the premium Leesa Legend, which promotes a mix of memory foam and micro-coil springs to keep you comfortable in any position you sleep in.
Discover it: Leesa
2. Sur La Table
This one is identified as merely a “summer season sale,” but the deals are excellent only through Memorial Day, so you must get to it quickly. This sale takes up to 20 percent off outdoor barbecuing and dining essentials, like cast-iron shrimp pans ($32), a stainless steel burger-grilling basket ($16), and, naturally, your option of barbeque sauce to go along with it.
Discover it: Sur la Table
Wayfair is cutting rates on all manner of home appliances up until May28 You can pretty much discover any house appliance imaginable at a low price, the sale is highlighted by $130 off a KitchenAid stand mixer and 62 percent off this eight-in-one GoWise air fryer.
Which’s only part of the brand name’s multiple Memorial Day sales, which you can search here They’re also taking up to 40 percent off Samsung refrigerators and cleaning devices, as much as 65 percent off living room furnishings, and up to 60 percent off bed mattress
Find it: Wayfair
4. Blue Apron
If you register for a Blue Apron membership prior to May 26, you’ll conserve $20 on each of your very first 3 box deliveries, amounting to $60 in savings.
Find it: Blue Apron
5. The PBS Store
Score 20 percent off sitewide at Shop.PBS.org when you use the promo code TAKE20 This slashes costs on everything from documentaries like Ken Burns’s The Roosevelt: An Intimate History($48) and The Civil War($64) to a Pride & Prejudice lug bag ($27) and this valuable heat-changing King Henry VIII mug ($11) that exposes the fates of his many wives when you pour your early morning coffee.
Find it: The PBS Shop
While Amazon doesn’t have a main Memorial Day sale, the ecommerce giant still has plenty of ever-changing deals to pick from. Right now, you can take $100 off this outside grill from Weber, $70 off a eufy robot vacuum, and 22 percent off the ASUS gaming laptop computer. For more offers, just go to Amazon and have a look around.
You can save approximately 50 percent on camping tents, treking packs, outdoor wear, and more from brand names like Patagonia, Marmot, and others throughout Backcountry’s Memorial Day sale.
Discover it: Backcountry
8. Entertainment Earth
From now up until June 2, Entertainment Earth is having a buy one, get one half off sale on choose Funko Pops. This includes stalwarts like the Star Wars and Batman lines, and more current additions like the Schitt’s Creek Funkos and the pre-orders for the upcoming X-Men movie line.
Find it: Home Entertainment Earth
With the discount code SUN BLOCK, you can take 20 percent off one full-price product at Moosejaw, in addition to finding up to 30 percent off select items during the outdoor brand’s summer sale. These offers include casual clothes, outside wear, path tennis shoes, and more.
Discover it: Moosejaw
Through May 25, you can conserve 25 percent on choose summertime items, and 40 percent off items from last season. This can consist of anything from hiking packs and baggage to outdoorsy socks and hats. If you’re preparing on getting familiarized with the great outdoors this summer season, now you can do it on the inexpensive.
Find it: Osprey
At Mental Floss, we just write about the items we love and wish to show our readers, so all products are chosen separately by our editors. Mental Floss has affiliate relationships with particular retailers and might receive a portion of any sale made from the links on this page. Costs and schedule are accurate as of the time of publication.
Welcome back to Cultivated, our weekly newsletter where we’re bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom.
Welcome back to Cultivated, everyone! I’m really excited to be back in your inboxes and I hope you’re all excited for your weekly rundown of the never boring, always entertaining, and sometimes fascinating cannabis industry.
For those of you who aren’t as online as me and probably missed all of my social media posts, I spent the last two months covering New York state’s response to the coronavirus pandemic as it quickly sucked up all the oxygen in the media — and our daily lives.
Thankfully, things are slowly stabilizing in New York City. Though we’re not out of the woods yet, cases are down, hospitals are getting back to normal, and the daily death counts are dropping. Let’s hope policymakers and healthcare workers do what they can to ensure those trends continue.
I’ve been playing lots of catch up with many of my sources this week and I’m sure there are lots of stories I’ve missed over the past two months.
Cannabis earnings — highlighted by Curaleaf and Trulieve — seem to have been a bright spot in the wider recession-tinged market. With more people stuck at home, (legal) cannabis seems like a good way to spice up your bread-baking sessions and The Office marathons.
I also participated in a Zoom panel with some top-tier cannabis reporters and PRs about opening up a better line of communication between publicists and the media. I think it was a constructive discussion and I hope you were able to watch.
Drop me a line if you have an idea of what I should be covering or who I should be speaking with. You can find my contact info below. We have lots of great stories coming next week.
Here’s what we wrote about:
The vehicle DraftKings used to go public has caught the eye of cannabis investors, who have poured nearly $3 billion into ‘blank check’ money
Investors targeting the cannabis industry are turning to special purpose acquisition companies, or SPACs, to chase down cannabis deals.
Most traditional investors, like pension-backed venture capital or private-equity firms, are reticent to invest the industry since cannabis is federally illegal in the US.
Investors have poured $2.8 billion into cannabis-focused SPACs since the start of 2019. The entire SPAC market over that time raised roughly $17.5 billion.
Investment in psychedelics has ramped up in recent years and companies say that interest from traditional biotech and pharma investors has picked up as well.
We identified the top nine companies that are working to turn psychedelics into approved medicines, for conditions like depression and anxiety.
- California cannabis manufacturer CannaCraft has added three new board members: Leon Sharyon, Mason Garrity, and Gareth Clark. Sharyon, notably, was the longtime CFO of Lagunitas Brewing.
- Champignon Brands, a startup developing ketamine and psychedelic therapies, announced a $10 million private placement with Canaccord Genuity and Eight Capital, two of the Canadian midsize investment banks that led cannabis capital markets from the beginning. Watch this space.
- 4Front Ventures, a cannabis company that has recently contended with executive churn and layoffs, found a lifeline: a $5.8 million private placement from cannabis investment fund Navy Capital, and an asset sale to Ethos Capital. Earlier in May, 4Front sold off $18 million in assets.
- Aurora Cannabis finally made its entrance into the US CBD market with the $40 million, all-stock purchase of Reliva LLC announced on Wednesday.
- Materia Ventures acquired 100% of German medical cannabis company Cannaktiv GmbH.
This one comes from Cowen’s cannabis analyst, Vivien Azer, in her US cannabis deep dive, citing data from the Center for Responsive Politics.
As you can see, cannabis companies spend slightly more proportionally than their “vice industry” peers on lobbying state and federal governments. In total, however, cannabis lobbying pales in comparison to alcohol and tobacco lobbying.
Cannabis companies spent $5.3 million on lobbying in 2019, compared to close to $30 million for tobacco and alcohol in 2019.
Cannabis short sellers down $641M in May (Benzinga)
The courtship in between Aurora Cannabis Inc. and Reliva began, as numerous such romances do, at an event of industry bigwigs and lenders.
It was not rather love at very first sight.
Well ahead of the very first conference at a 2019 conference run by an investment bank, Aurora
had actually been buying a way to get in the U.S. market for some time, stating so openly on incomes calls and in interviews with MarketWatch. However it took Aurora months to seriously vet Reliva as an acquisition target, the presidents at both companies informed MarketWatch in a telephone interview this week.
Months after that first conference, Aurora’s executive team flew to Boston and consulted with Reliva, a business that focuses on cannabidiol, or CBD. For 48 hours, bosses from Aurora and Reliva visited wholesale and bricks-and-mortar shops and talked about business, with Aurora interim CEO Michael Vocalist telling MarketWatch they discovered enough in those two days to begin seriously assessing Reliva.
More on the offer: Aurora Marijuana makes long-awaited push into U.S. with Reliva acquisition
” We discovered a lot about Miguel [Martin] and a lot about the Reliva story, and he got to discover the Aurora corporate story,” Vocalist stated in a telephone interview. “When we consider [Aurora’s] reset plan, we believe this was an accountable and tactical acquisition. It’s not practically the U.S.”
Aurora’s lawyers worked furiously to veterinarian Reliva, having a look at its operations, personnel and intellectual property, though Singer says there was not much IP to consider. Reliva CEO Miguel Martin and other top staff visited Aurora’s board in Toronto– at a time when that was still possible– and several “long and thoughtful discussions” took place prior to both sides became comfortable sufficient to wed, Vocalist said.
Carefully held Reliva had already been trying to draw in capital: it had actually been out searching for cash at $40 million pre-money evaluation from investor, to name a few, according to two individuals familiar with the matter. That would be roughly 3 times Reliva’s yearly revenue of $13 million to $14 million, Aurora confirmed Friday.
Instead, Reliva accepted $40 million in Aurora stock to sell the company outright, with another $45 million in prospective earn-outs, as the companies revealed Wednesday. When Aurora announced the offer, its mainly retail investor base responded positively, bidding up the rate of Aurora stock after shares had actually currently published two days of 50%gains in response to its revenues report.
If effective, the acquisition will assist Aurora develop a beachhead in the U.S. through a CBD possession and help to grow its partnership with Ultimate Fighting Championship, which is owned by a number of closely held venture-capital firms. Jefferies lowered its rate target on Aurora stock to C$12($ 9.
In a note to clients Friday, Jefferies analyst Owen Bennett wrote that the deal’s timing and this particular acquisition is odd and the business’s focus on adjusted revenues warrants a “close appearance.” In the news release announcing the offer, Aurora promoted Reliva as “profitable,” but Vocalist told MarketWatch it suggested on an adjusted basis, not utilizing basic accounting.
” There is still no long-term CEO to lead this CBD push, the CBD space is experiencing substantial headwinds currently, there is more dilution at a questionable multiple which has been a criticism of the past,” Bennett wrote. “Even more, it potentially clouds the true underlying [earnings before interest taxes deductions amortization] shipment in [the first quarter] which could now be propped up by this deal.”
Reliva runs in a congested market– there are most likely hundreds of business in the U.S. making cannabidiol, or CBD products– that is difficult to stand out in. While Aurora cited a report predicting the “CBD opportunity” to be $24 billion, the U.S. Food and Drug Administration has actually not issued clear assistance on the compound.
Martin states that while the FDA’s stance is essential, he’s equally concentrated on state legalization– 41 have passed laws around CBD, which is a nonintoxicating substance found in the cannabis plant.
Reliva makes CBD items, but its true strength lies in its distribution network. Martin states that there have to do with 50,000 stores that offer CBD in the U.S. at the moment, and his company is offering items in 20,000 of them. And when Martin speak about shops, he’s referring to convenience stores like Circle K, which is owned by Alimentation Couche-Tard Inc.
, a multinational operator of corner store based in Laval, Quebec.
Martin states the company’s primary pitch for its items is that they are cheap: they’re all under $20, while rival Lord Jones, which was gotten by Cronos Group Inc.
sells 30 gel pills for $95
Rate could be essential amidst the COVID-19 pandemic, with Martin noting that disposable incomes are down. It could also injure business in general, though, as Martin confessed that the pandemic has affected sales with a major decline in foot traffic at corner store.
Martin stated products have remained for sale, however the effect is unclear for the busy season– that’s May to September for the sorts of retailers on which Reliva relies. The summer months tend to be more profitable rather just because the weather condition is much better.
” We have a seasonal business,” Martin said in a telephone interview.
A team of scientists from Canada have actually recognized a minimum of 13 pressures of cannabis sativa they think can assist in the prevention and treatment of COVID-19
The mission for a COVID-19 drug that will both make Donald Trump and his pals in the pharmaceutical industry abundant and not eliminate the people who take it has, so far, netted no results. Exciting government-sponsored research out of Canada appears to indicate a different approach is in order.
Per the team’s term paper:
We have established over 800 new Cannabis sativa lines and extracts and hypothesized that high-CBD C. sativa extracts may be utilized to regulate ACE2 expression in COVID-19 target tissues.
What this suggests is the group has thoroughly established several marijuana stress that have been experimentally shown to make it significantly more difficult for the SARS-CoV2 coronavirus to find a house inside of the tissue cells it latches onto in order to contaminate us with the COVID-19 disease.
It does not mean you should go out to your local dispensary and exhaust their sativa and CBD supply. The 13 stress cultivated by the scientists are likely very various from whatever wacky-named stress you’re going to acquire nonprescription. If you should take an untried treatment, I advise taking Canada’s lead and lawfully imbibing cannabis rather of listening to the Trump administration
[Read: Don’t drink bleach]
A current research study led by Harvard Medical School teacher Mandeep Mehra which took a look at information from more than 96,000 COVID-19 patients, 15,000 of which had actually been treated with hydroxychloroquine, plainly showed that patients using the drug were at far higher danger for death than those who did not. Per a report from the Washington Post:
For those offered hydroxychloroquine, there was a 34 percent increase in risk of death and a 137 percent increased risk of a serious heart arrhythmias. For those getting hydroxychloroquine and an antibiotic– the cocktail endorsed by Trump– there was a 45 percent increased danger of death and a 411 percent increased threat of major heart arrhythmias.
Those offered chloroquine had a 37 percent increased risk of death and a 256 percent increased risk of serious heart arrhythmias. For those taking chloroquine and an antibiotic, there was a 37 percent increased threat of death and a 301 percent increased risk of serious heart arrhythmias.
Donald Trump recently told reporters and the US public that he ‘d been taking hydroxycholoroquine as a preventative step to ward off COVID-19 Excepting the reality he has a small financial stake in Plaquenil– the drug name for hydroxycholoroquine– if he actually wants to avoid COVID-19 he should imbibe marijuana. There’s no peer-reviewed proof showing it’ll work, however a minimum of it won’t kill him.
” I want the people of this nation to feel great. I do not want them being ill”– Trump claims the White House physician validated him taking hydroxychloroquine, which he says he was motivated to begin taking because of letters he got pic.twitter.com/R0oKn9XMpP
— Aaron Rupar (@atrupar) May 18, 2020
Not just has nobody ever passed away from imbibing cannabis, it has clear medical benefits for the prevention and treatment of diseases ranging from viral infections to cancer. That, and he might be less of an asshole if he smoked a joint every now and then.
For additional information on the cannabis study, have a look at the complete pre-print term paper here And if you want to know more about why nobody needs to utilize hydroxycholorquine to avoid or deal with COVID-19, please read this essential study
Wellness start-up Present Life launches Healist Advanced Naturals, a medically supported CBD variety, with a cut-through brand method that weds science and nature by Robotic Food. Given that constraints on the use of cannabidiol (the non-intoxicating part of cannabis) were lifted in Europe and North America, the CBD health sector has actually blown up. Experts are now anticipating that the international market will exceed ₤72 billion by 2026– and sales of CBD-based items in the retail sector will be a significant chauffeur of that development. As a result, the marketplace is becoming increasingly congested and baffled, with a proliferation of balms, oils, and tinctures in differing portion strengths, guaranteeing to correct any variety of health issues. Present Life wished to develop a product line that took advantage of this sector growth, but in a manner that alters the narrative around CBD products, eliminates confusion, shows integrity, and makes the health advantages crystal clear to the customer. Robot Food was approached to drill down and specify the opportunity, and after that devise a strategic reaction to place Healist as a benefit-focused flagship brand name with multichannel selling in mind. The resulting work has actually allowed Healist to cut through all the white noise. Customers are reassured of the high-quality nature of the products, and have the ability to navigate the range quickly to discover the ideal version for their needs. “A shift in policies and consumer frame of mind have sustained a sharp growth in the CBD classification, so we required to develop a brand with unique cut-through. It was essential to remove the typical barriers connected with CBD products, construct trust and make it mainstream,” states Simon Forster, executive imaginative director and creator of Robotic Food. A crucial part of the technique was to show the advantages to be discovered where contemporary science and botanical know-how meet, and demonstrate how that marital relationship can help consumers gain back balance and ‘reclaim their 100%’. To that end, the fusion message is evident at every touchpoint on the consumer journey. The bespoke packaging format makes a real virtue of the science and nature story and focuses on the effectiveness of the ingredients. A lab-white ‘science’ sleeve with a diecut ‘H’ is gotten rid of to expose the ‘nature’ layer, featuring botanical illustrations that showcase active components, with 4 colourways so customers can quickly distinguish the 4 main benefits (calm, sleep, well-being, relief). “The ‘H’ marque records Healist’s spirit. One pillar represents science, the other nature, while a central dot signs up with the 2 and is symbolic of balance,” states Steph Oglesby, style director at Robotic Food. Robot Food has created a brand world and intonation to support the USP and inspire trust, with messaging that includes hero declarations like: “Ground-breaking science. It remains in our nature” and “Powerful natural ingredients. Down to a science.” From product packaging right through to the brand name communication method, scientific hints, including annotation lines and botanical illustrations, produce a structure that strengthens the power of nature when blended with a clinical technique. “We’ve created and launched our own brand names at Robotic Food, so we had the ability to determine the more comprehensive opportunity within the marketplace,” states Forster. “The majority of CBD brand names focus their technique on the percentage of CBD oil, or line up to a particular lifestyle. With Healist, we put the customer first, creating benefit-led solutions presented in a brand name architecture that bridges science and wellness.” Michael Bryce, co-founder and international chief marketing officer, Healist, states: “Dealing with Robotic Food helped us clarify and fully understand our special market position. As a firm, the team at Robot Food always has front of mind industrial viability in addition to strong, appealing style. The brand name method can flex and grow as we do too.” Part of a continuous relationship with Present Life, Robot Food will continue to support Healist with digital material development, and function as brand guardians. Released online in March, Healist prepares to burglarize traditional merchants in the United States, followed by the European market based on the modifications to CBD regulations.